Halofenate [26718-25-2]

MedChem Express

Halofenate [26718-25-2]

5

26718-25-2

Research Use Only

C19H17ClF3NO4

415.79

Halofenate, structurally akin to clofibrate, was evaluated in hypertriglyceridemic patients over 6-week periods in a controlled, double-blind crossover trial. It effectively reduced serum triglycerides by 50%, with minimal impact on serum cholesterol levels. Additionally, it lowered serum uric acid by 30% and exhibited uricosuric effects independent of glomerular filtration rate. Halofenate was associated with a significant increase in plasma thyroxine (T4), accompanied by a decrease in protein-bound iodine and T4 by column. In vitro studies confirmed its ability to displace T4 from thyroid-binding proteins, suggesting a thyroxine-displacing effect, which could influence thyroid function in vivo[1].

CC(NCCOC(C(C1=CC=C(Cl)C=C1)OC2=CC=CC(C(F)(F)F)=C2)=O)=O

12131703